eJHaem (Nov 2022)
Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
- Muhamed Baljevic,
- Cristina Gasparetto,
- Gary J. Schiller,
- Sascha A. Tuchman,
- Natalie S. Callander,
- Suzanne Lentzsch,
- Jorge Monge,
- Rami Kotb,
- Nizar J. Bahlis,
- Darrell White,
- Christine I. Chen,
- Heather J. Sutherland,
- Sumit Madan,
- Richard LeBlanc,
- Michael Sebag,
- Christopher P. Venner,
- William I. Bensinger,
- Noa Biran,
- Andrew DeCastro,
- Dane R. Van Domelen,
- Chris Zhang,
- Jatin J. Shah,
- Sharon Shacham,
- Michael G. Kauffman,
- Ohad S. Bentur,
- Brea Lipe
Affiliations
- Muhamed Baljevic
- Vanderbilt‐Ingram Cancer Center Vanderbilt University Medical Center Nashville Tennessee USA
- Cristina Gasparetto
- Duke Cancer Institute Duke University Durham North Carolina USA
- Gary J. Schiller
- Hematological Malignancy/Stem Cell Transplant Program University of California ‐ Los Angeles David Geffen School of Medicine Los Angeles California USA
- Sascha A. Tuchman
- Department of Medicine Division of Hematology The University of North Carolina at Chapel Hill Chapel Hill North Carolina USA
- Natalie S. Callander
- Division of Hematology/Oncology, Department of Medicine University of Wisconsin‐Madison School of Medicine and Public Health Madison Wisconsin USA
- Suzanne Lentzsch
- Columbia University Medical Center New York New York USA
- Jorge Monge
- Weill Cornell Medicine New York New York USA
- Rami Kotb
- Medical Oncology and Hematology CancerCare Manitoba Winnipeg Manitoba Canada
- Nizar J. Bahlis
- Arnie Charbonneau Cancer Research Institute University of Calgary Calgary Alberta Canada
- Darrell White
- Department of Medicine/Division of Hematology Dalhousie University Halifax Nova Scotia Canada
- Christine I. Chen
- Princess Margaret Cancer Centre Toronto Ontario Canada
- Heather J. Sutherland
- Division of Hematology Vancouver General Hospital Vancouver British Columbia Canada
- Sumit Madan
- Banner MD Anderson Cancer Center Gilbert Arizona USA
- Richard LeBlanc
- Maisonneuve‐Rosemont Hospital University of Montreal Montreal Québec Canada
- Michael Sebag
- Division of Hematology McGill University Health Centre Montreal Québec Canada
- Christopher P. Venner
- Cross Cancer Institute University of Alberta Edmonton Alberta Canada
- William I. Bensinger
- Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute Seattle Washington USA
- Noa Biran
- John Theurer Cancer Center, Hackensack Meridian Health Hackensack University Medical Center Hackensack New Jersey USA
- Andrew DeCastro
- Karyopharm Therapeutics Inc. Newton Massachusetts USA
- Dane R. Van Domelen
- Karyopharm Therapeutics Inc. Newton Massachusetts USA
- Chris Zhang
- Karyopharm Therapeutics Inc. Newton Massachusetts USA
- Jatin J. Shah
- Karyopharm Therapeutics Inc. Newton Massachusetts USA
- Sharon Shacham
- Karyopharm Therapeutics Inc. Newton Massachusetts USA
- Michael G. Kauffman
- Karyopharm Therapeutics Inc. Newton Massachusetts USA
- Ohad S. Bentur
- Karyopharm Therapeutics Inc. Newton Massachusetts USA
- Brea Lipe
- Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA
- DOI
- https://doi.org/10.1002/jha2.572
- Journal volume & issue
-
Vol. 3,
no. 4
pp. 1270 – 1276
Abstract
Abstract There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti‐BCMA‐targeted chimeric antigen receptor‐T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA‐antibody‐drug conjugate therapy. We observe that X‐containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients’ prior anti‐BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X‐based regimens following broader anti‐BCMA therapy.
Keywords
